Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT

Anastasia Papadopoulou; Ulrike Gerdemann; Usha L. Katari; Ifigenia Tzannou; Hao Liu; Caridad Martinez; Kathryn Leung; George Carrum; Adrian P. Gee; Juan F. Vera; Robert A. Krance; Malcolm K. Brenner; Cliona M. Rooney; Helen E. Heslop; Ann M. Leen

doi:10.1126/scitranslmed.3008825

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT

Anastasia Papadopoulou, Ulrike Gerdemann, Usha L. Katari, Ifigenia Tzannou, Hao Liu, Caridad Martinez, Kathryn Leung, George Carrum, Adrian P. Gee, Juan F. Vera, Robert A. Krance, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop, Ann M. Leen

Research output: Contribution to journal › Article › peer-review

330 Scopus citations

Abstract

It remains difficult to treat the multiplicity of distinct viral infections that afflict immunocompromised patients. Adoptive transfer of virus-specific T cells (VSTs) can be safe and effective, but such cells have been complex to prepare and limited in antiviral range. We now demonstrate the feasibility and clinical utility of rapidly generated single-culture VSTs that recognize 12 immunogenic antigens from five viruses (Epstein-Barr virus, adenovirus, cytomegalovirus, BK virus, and human herpesvirus 6) that frequently cause disease in immunocompromised patients. When administered to 11 recipients of allogeneic transplants, 8 of whom had up to four active infections with the targeted viruses, these VSTs proved safe in all subjects and produced an overall 94% virological and clinical response rate that was sustained long-term.

Original language	English (US)
Article number	242ra83
Journal	Science translational medicine
Volume	6
Issue number	242
DOIs	https://doi.org/10.1126/scitranslmed.3008825
State	Published - Jun 25 2014

ASJC Scopus subject areas

General Medicine

Access to Document

10.1126/scitranslmed.3008825

Cite this

Papadopoulou, A., Gerdemann, U., Katari, U. L., Tzannou, I., Liu, H., Martinez, C., Leung, K., Carrum, G., Gee, A. P., Vera, J. F., Krance, R. A., Brenner, M. K., Rooney, C. M., Heslop, H. E., & Leen, A. M. (2014). Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Science translational medicine, 6(242), Article 242ra83. https://doi.org/10.1126/scitranslmed.3008825

Papadopoulou, A, Gerdemann, U, Katari, UL, Tzannou, I, Liu, H, Martinez, C, Leung, K, Carrum, G, Gee, AP, Vera, JF, Krance, RA, Brenner, MK, Rooney, CM, Heslop, HE & Leen, AM 2014, 'Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT', Science translational medicine, vol. 6, no. 242, 242ra83. https://doi.org/10.1126/scitranslmed.3008825

@article{09ddfe2edd7d4d2ebf0aa813621bf08c,

title = "Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT",

abstract = "It remains difficult to treat the multiplicity of distinct viral infections that afflict immunocompromised patients. Adoptive transfer of virus-specific T cells (VSTs) can be safe and effective, but such cells have been complex to prepare and limited in antiviral range. We now demonstrate the feasibility and clinical utility of rapidly generated single-culture VSTs that recognize 12 immunogenic antigens from five viruses (Epstein-Barr virus, adenovirus, cytomegalovirus, BK virus, and human herpesvirus 6) that frequently cause disease in immunocompromised patients. When administered to 11 recipients of allogeneic transplants, 8 of whom had up to four active infections with the targeted viruses, these VSTs proved safe in all subjects and produced an overall 94% virological and clinical response rate that was sustained long-term.",

author = "Anastasia Papadopoulou and Ulrike Gerdemann and Katari, {Usha L.} and Ifigenia Tzannou and Hao Liu and Caridad Martinez and Kathryn Leung and George Carrum and Gee, {Adrian P.} and Vera, {Juan F.} and Krance, {Robert A.} and Brenner, {Malcolm K.} and Rooney, {Cliona M.} and Heslop, {Helen E.} and Leen, {Ann M.}",

year = "2014",

month = jun,

day = "25",

doi = "10.1126/scitranslmed.3008825",

language = "English (US)",

volume = "6",

journal = "Science translational medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "242",

}

TY - JOUR

T1 - Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT

AU - Papadopoulou, Anastasia

AU - Gerdemann, Ulrike

AU - Katari, Usha L.

AU - Tzannou, Ifigenia

AU - Liu, Hao

AU - Martinez, Caridad

AU - Leung, Kathryn

AU - Carrum, George

AU - Gee, Adrian P.

AU - Vera, Juan F.

AU - Krance, Robert A.

AU - Brenner, Malcolm K.

AU - Rooney, Cliona M.

AU - Heslop, Helen E.

AU - Leen, Ann M.

PY - 2014/6/25

Y1 - 2014/6/25

N2 - It remains difficult to treat the multiplicity of distinct viral infections that afflict immunocompromised patients. Adoptive transfer of virus-specific T cells (VSTs) can be safe and effective, but such cells have been complex to prepare and limited in antiviral range. We now demonstrate the feasibility and clinical utility of rapidly generated single-culture VSTs that recognize 12 immunogenic antigens from five viruses (Epstein-Barr virus, adenovirus, cytomegalovirus, BK virus, and human herpesvirus 6) that frequently cause disease in immunocompromised patients. When administered to 11 recipients of allogeneic transplants, 8 of whom had up to four active infections with the targeted viruses, these VSTs proved safe in all subjects and produced an overall 94% virological and clinical response rate that was sustained long-term.

AB - It remains difficult to treat the multiplicity of distinct viral infections that afflict immunocompromised patients. Adoptive transfer of virus-specific T cells (VSTs) can be safe and effective, but such cells have been complex to prepare and limited in antiviral range. We now demonstrate the feasibility and clinical utility of rapidly generated single-culture VSTs that recognize 12 immunogenic antigens from five viruses (Epstein-Barr virus, adenovirus, cytomegalovirus, BK virus, and human herpesvirus 6) that frequently cause disease in immunocompromised patients. When administered to 11 recipients of allogeneic transplants, 8 of whom had up to four active infections with the targeted viruses, these VSTs proved safe in all subjects and produced an overall 94% virological and clinical response rate that was sustained long-term.

UR - http://www.scopus.com/inward/record.url?scp=84903752045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903752045&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3008825

DO - 10.1126/scitranslmed.3008825

M3 - Article

C2 - 24964991

AN - SCOPUS:84903752045

SN - 1946-6234

VL - 6

JO - Science translational medicine

JF - Science translational medicine

IS - 242

M1 - 242ra83

ER -

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this